Apertura Gene Therapy’s Post

A NEW TOOL is helping scientists investigate how cells relate with their neighbors within the tumor environment. The tool, known as COVET, provides a more complete representation of gene expression in niche cells, letting researchers apply powerful existing analysis tools to reveal how cells relate with their neighbors within the tumor environment. Learn more: http://spr.ly/6049gSF5x

Looking forward to seeing everyone in London soon! Check out our presentation on day 2: “Bespoke discovery of novel human promoters for improved safety and efficacy in gene and cell therapy”

Thank you Lung-I Cheng for facilitating this robust discussion at Reuters Events Pharma about the value of #patient engagement in #cell and #gene therapy development. Key takeaways included: *Innovative study designs, such as leveraging #RWE, is needed to develop treatments for rare diseases which often have small patient populations. *Leveraging information from #FDA's patient focused drug development meetings is important to understanding the patient experience. *The rapid development of #CGTs is a paradigm shift for many regulating bodies, and risk-based flexability is needed to ensure timely #patient #access. *Long-term patient follow up remains a challenge, but the value of capturing patient #data remains a priority. Fellow Panelists: Olga Granaturova, Co-founder, President, PriveBio Jeffrey Meckler, Chief Executive Officer, Indaptus Therapeutics Jason Lott, MD MSHP MHS FAAD, VP, Global Integrated Evidence Generation, Specialty Medicine, Integrated Care, and Cell-Gene Therapy, Bayer Special thanks to my colleagues American Society of Gene & Cell Therapy for supporting my participation at events on this important topic. #ASGCT #ASGCTadvocacy #CellTherapy #GeneTherapy

👏 👏👏 Please watch the video and read the blog post.

This early warning system provides a significant time advantage over traditional screening methods, potentially allowing for more effective preventive measures and treatment strategies. The test focuses on subtle changes at the molecular level, capturing the initial stages of cellular transformation towards cancer. By monitoring shifts in gene expression patterns associated with precancerous conditions, we can flag potential issues long before they manifest as visible structural changes or abnormal cytology results. https://lnkd.in/gW6akYv2 #ceevicalcancer

One of the annual conference highlights! You'll find me in the sessions, at the posters, at the morning run - and of course at the TATAA Biocenter booth. If you want to better plan your visit, simply e-mail to lukas.paul@tataa.com to schedule a meeting. Let's review how we can enable and accelerate your projects with expert #bioanalysis! #ESGCT2024

One week to go for #ESGCT! Many years ago I heard from a potential customer to services I was promoting saying: "I need an early success or an early failure: either one will tell me what to do next"...so WHAT ARE YOU WAITING FOR...? ...is your bioanalysis service provider taking too long to provide critical information regarding your precious clinical/pre-clinical samples? ...are you unsure about the selected method of sample preparation for your #biodistribution study...? ...have you been made aware how nucleic acid #extraction, the assay design, and #optimization process are can all have impact on the #quality of the results you have contracted to have...? ...do you need to have #answers sooner rather than later...? If any of these questions made you think, reach out or better: come to #Rome and meet the TATAA Biocenter team: we are at booth #A02! ...AND DON'T WAIT FOR THE REGULATORS TO CALL/EMAIL YOU, it will probably be too late ... #BETTERLATETHANNEVER #research #medicine #cancer #cro #glp #quality #lifesciences #drugdiscovery #pharma #biotech #biopharma

#Gene and #cell-based therapies have the potential to provide targeted and personalized treatments, according to Charité - Universitätsmedizin Berlin and Bayer. They are a beacon of hope for people for whom conventional therapies have failed or for whom there is no treatment so far. With Charité and Bayer, two partners for major medical progress are coming together who will establish a new center for gene and cell therapy in #Berlin, which is to be established in 2025. More information in first comment #healthforall #teambayer

Take a look at this article, co-authored by Zhe Liu, PhD, Labcorp staff scientist, which focuses on development of a preclinical anti-AAV antibody assay to enable screening for pre-existing AAV immunity. Discover how this assay can help gene therapy developers identify potential low-responding individuals, increase the likelihood of successful transduction and maximize the utility of the preclinical investigations. Read the full article: http://spr.ly/6040pXp5E #GeneTherapy #AAV #CellandGeneTherapy

  Landmark Bio’s Eli Kraus, Yun Chen,Ph.D., Manish Tandon and Gregg Nyberg, demonstrate application of a rapid analytical method in cutting-edge Extracellular Vesicle (EV)-based therapy biomanufacturing. Based on widely available conventional Flow Cytometer configurations, the method development was presented at the ECI Advancing Manufacture of Cell and Gene Therapies Conference in Coronado, CA. Read about the accuracy, precision, and reliable EV quantitation by Flow Cytometry, its benefit, criticality, and limitation in directly supporting clinical EV biomanufacturing platforms. #ExtracellularVesicles #FlowCytometry